Synkrino Development Company, LLC | 155 followers on LinkedIn. SDC partners with innovative biotechs to develop novel, high impact therapeutics thru to the clinic - and to patients. | Synkrino Development Company (SDC) partners with biotech to finance and develop innovative high impact therapeutics programs. We serve the entire pharma ecosystem of patients, prescribers, payers, biotechs, and pharma companies by financing, accelerating, and pushing forward drug candidates with the potential to significantly improve the standard of care – offering a new range of therapeutic options that balance price and treatment outcome. Our process creates portfolios of orthogonal assets (biological target, disease indication, modality) with the aim of de-risking biotech investments for institutional investors.